Brief: Organogenesis Reports Positive Interim Analysis Of Phase 3 Clinical Trial Of Renu For Knee Osteoarthritis
01/03/2023 21:54
March 1 (Reuters) - Organogenesis Holdings Inc ORGO.O :
* ORGANOGENESIS REPORTS POSITIVE INTERIM ANALYSIS OF PHASE 3
CLINICAL TRIAL OF RENU FOR KNEE OSTEOARTHRITIS
* ORGANOGENESIS REPORTS POSITIVE INTERIM ANALYSIS OF PHASE 3
CLINICAL TRIAL OF RENU FOR KNEE OSTEOARTHRITIS
* ORGANOGENESIS HOLDINGS INC - DMC FOUND SAFETY DATA TO BE
CONSISTENT WITH KNOWN SAFETY PROFILE FOR RENU
Source text for Eikon: ID:nGNXgP0TN
Further company coverage: ORGO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Organogenesis Holdings
See all newsBrief: Organogenesis Announces Publication Of Peer-Reviewed Prepare Trial Results
Organogenesis Holdings Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Organogenesis Q2 Net Product Revenue USD 42.8 Million
Organogenesis Holdings Inc. expected to post a loss of 35 cents a share - Earnings Preview
Brief: Organogenesis Announces Publication Of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit Of Affinity™ In The Most Challenging And Complex Venous Leg Ulcers